Volume 4 (2020)
Free open-access journal.
|
| Price of the complete print-issue: 0.00$ |
Add to Cart
|
Original
“New” inhalant plant allergens
Stefani T.M. Röseler, Jens M. Baron, Conny Höflich, Hans F. Merk, Murat Bas, Henning Bier, Wolfgang Dott, Katharina Fietkau, Zuzanna Hajdu, Lorraine Kaiser, Thomas Kraus, Gottfried Laven, Silke Moll-Slodowy, Hans-Guido Mücke, Wolfgang Straff, Gerda Wurpts, Amir S. Yazdi, Adam Chaker, and Galina Balakirski
Page No. 1
Abstract
Allergologie select, Volume 4/2020 (1-10)
“New” inhalant plant allergens
Stefani T.M. Röseler1,2, Jens M. Baron2, Conny Höflich3, Hans F. Merk2, Murat Bas4, Henning Bier†, Wolfgang Dott5, Katharina Fietkau2, Zuzanna Hajdu6, Lorraine Kaiser3, Thomas Kraus5, Gottfried Laven5, Silke Moll-Slodowy2, Hans-Guido Mücke3, Wolfgang Straff3, Gerda Wurpts2, Amir S. Yazdi2, Adam Chaker7, and Galina Balakirski2,8
1Department of Pneumology, Allergology, Sleep and Respiratory Medicine, Augustinians Hospital, Cologne, 2Department of Dermatology and Allergology, University Hospital of RWTH Aachen, Aachen, 3Federal Environment Agency, Section II 1.5 Environmental Medicine and Health Effects Assessment, Berlin, 4Otorhinolaryngology Practice, Ottobrunn, 5Department of Environmental Medicine, University Hospital of RWTH Aachen, Aachen, 6Department of Otorhinolaryngology, Helios-Amper Clinic Dachau, Dachau, 7Department of Otorhinolaryngology, Hospital Rechts der Isar, Technical University Munich, Munich, and 8Department of Dermatology and Allergology, University Hospital of Bonn, Bonn, Germany
Specific IgE measurements obtained from patients suffering from respiratory allergy (n = 952) show that, despite similar climatic conditions, there are clear regional differences in pollen sensitization between North Rhine-Westphalia and Bavaria. The data on sensitization levels and pollen concentration was taken from the research and development project Ufoplan 3710 61 228 of the German Environment Agency for North Rhine-Westphalia and Bavaria (2011 – 2014). Most poly-sensitized patients have already shown sensitization, both in the form of cross-reactivity and species-specific sensitization, to “new” pollen allergens, such as Bermuda grass and olive tree. These plants are currently not common in Germany, but may become considerably more widespread due to the increase in average yearly temperatures caused by the global warming. The other “new” aeroallergens discussed here are plants that can be found throughout Germany, such as nettle, cypress, and pine. Their current sensitization levels are higher than 8%; however, their clinical impact appears to be underestimated. For clinical practice it is important to identify when patients’ symptoms are typically severe and which regional plants might be responsible for the patients’ complaints in this period of time, as this affects further diagnostic strategy. Allergens having an immune effect can then be targeted by specific immunotherapies. The information on complaints of the patients should be regularly recorded in symptom diaries. Recording this information for at least 1 year may allow to discover a correlation between specific types of pollen and allergy symptoms.Correspondence to:
Dr. med. Stefani Röseler, Department of Pneumology, Allergology, Sleep and Respiratory Medicine, Augustinians Hospital, Cologne, Germany
Email: [email protected]
Original
Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics
Gerda Wurpts, Werner Aberer, Heinrich Dickel, Randolf Brehler, Thilo Jakob, Burkhard Kreft, Vera Mahler, Hans F. Merk, Norbert Mülleneisen, Hagen Ott, Wolfgang Pfützner, Stefani Röseler, Franziska Ruëff, Helmut Sitter, Cord Sunderkötter, Axel Trautmann, Regina Treudler, Bettina Wedi, Margitta Worm, und Knut Brockow
Page No. 11
Abstract
Allergologie select, Vol. 4/2020 (11-43)
Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics
Gerda Wurpts1, Werner Aberer2, Heinrich Dickel3, Randolf Brehler4, Thilo Jakob5, Burkhard Kreft6, Vera Mahler7,8, Hans F. Merk1, Norbert Mülleneisen9, Hagen Ott10, Wolfgang Pfützner11, Stefani Röseler1, Franziska Ruëff12, Helmut Sitter13, Cord Sunderkötter6, Axel Trautmann14, Regina Treudler15, Bettina Wedi16, Margitta Worm17, und Knut Brockow18
1Clinic for Dermatology and Allergology, Aachen Comprehensive Allergy Center (ACAC), Uniklinik RWTH Aachen, Germany 2Department of Dermatology, Graz Medical University, Graz, Austria, 3Department of Dermatology, Venereology and Allergology, St. Josef Hospital, University Hospital of the Ruhr University Bochum, Bochum, 4Department of Dermatology, University Hospital Münster, Münster, 5Department of Dermatology and Allergology, University Hospital Gießen und Marburg, Gießen Site, Gießen, 6Department of Dermatology and Venereology, University, Hospital Halle (Saale), Halle (Saale), 7Paul-Ehrlich Institute, Langen, 8Department of Dermatology, University Hospital Erlangen, Erlangen, 9Asthma and Allergy Centre, Leverkusen, 10Division of Pediatric Dermatology and Allergology, Auf der Bult Children’s Hospital, Hannover, 11Department of Dermatology and Allergology, University Hospital Gießen und Marburg, Marburg Site, Marburg, 12Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, 13Institute of Surgical Research, Philipps University Marburg, Marburg, 14Department of Dermatology and Allergy, Allergy Center Mainfranken, University Hospital Würzburg, Würzburg, 15Department of Dermatology, Venereology, and Allergology and Leipzig Interdisciplinary Center for Allergology – LICA-CAC, University of Leipzig, Leipzig, 16Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, 17Department of Dermatology, Venereology, and Allergology, Charité University Hospital Berlin, Allergy Center Charité (ACC), Berlin, and 18Department of Dermatology and Allergology am Biederstein, School of Medicine, Technical University of Munich, Munich, Germany
This guideline on diagnostic procedures for suspected beta-lactam antibiotic (BLA) hypersensitivity was written by the German and Austrian professional associations for allergology, and the Paul-Ehrlich Society for Chemotherapy in a consensus procedure according to the criteria of the German Association of Scientific Medical Societies. BLA such as penicillins and cephalosporins represent the drug group that most frequently triggers drug allergies. However, the frequency of reports of suspected allergy in patient histories clearly exceeds the number of confirmed cases. The large number of suspected BLA allergies has a significant impact on, e.g., the quality of treatment received by the individual patient and the costs to society as a whole. Allergies to BLA are based on different immunological mechanisms and often manifest as maculopapular exanthema, as well as anaphylaxis; and there are also a number of less frequent special clinical manifestations of drug allergic reactions. All BLA have a beta-lactam ring. BLA are categorized into different classes: penicillins, cephalosporins, carbapenems, monobactams, and beta-lactamase inhibitors with different chemical structures. Knowledge of possible cross-reactivity is of considerable clinical significance. Whereas allergy to the common beta-lactam ring occurs in only a small percentage of all BLA allergic patients, cross-reactivity due to side chain similarities, such as aminopenicillins and aminocephalosporins, and even methoxyimino cephalosporins, are more common. However, the overall picture is complex and its elucidation may require further research. Diagnostic procedures used in BLA allergy are usually made up of four components: patient history, laboratory diagnostics, skin testing (which is particularly important), and drug provocation testing. The diagnostic approach – even in cases where the need to administer a BLA is acute – is guided by patient history and risk – benefit ratio in the individual case. Here again, further studies are required to extend the present state of knowledge. Performing allergy testing for suspected BLA hypersensitivity is urgently recommended not only in the interests of providing the patient with good medical care, but also due to the immense impact of putative BLA allergies on society as a whole.Correspondence to:
Dr. med. Gerda Wurpts, Clinic for Dermatology and Allergology, Aachen Comprehensive Allergy Center (ACAC), Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany
Email: [email protected]
Position Paper
Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA
Ludger Klimek, Oliver Pfaar, Margitta Worm, Karl-Christian Bergmann, Thomas Bieber, Roland Buhl, Jeroen Buters, Ulf Darsow, Thomas Keil, Jörg Kleine-Tebbe, Susanne Lau, Marcus Maurer, Hans Merk, Ralph Mösges, Joachim Saloga, Petra Staubach, Petra Stute, Klaus Rabe, Uta Rabe, Claus Vogelmeier, Tilo Biedermann, Kirsten Jung, Wolfgang Schlenter, Johannes Ring, Adam Chaker, Wolfgang Wehrmann, Sven Becker, Norbert Mülleneisen, Katja Nemat, Wofgang Czech, Holger Wrede, Randolf Brehler, Thomas Fuchs, Peter-Valentin Tomazic, Werner Aberer, Antje Fink-Wagner, Friedrich Horak, Stefan Wöhrl, Verena Niederberger-Leppin, Isabella Pali-Schöll, Wolfgang Pohl, Regina Roller-Wirnsberger, Otto Spranger, Rudolf Valenta, Mübecell Akdis, Cezmi Akdis, Karin Hoffmann-Sommergruber, Marek Jutel, Paolo Matricardi, FranÇois Spertini, Nikolai Khaltaev, Jean-Pierre Michel, Laurent Nicod, Peter Schmid-Grendelmeier, Eckard Hamelmann, Thilo Jakob, Thomas Werfel, Martin Wagenmann, Christian Taube, Michael Gerstlauer, Christian Vogelberg, Jean Bousquet, and Torsten Zuberbier
Page No. 44
Abstract
Allergologie select, Volume 4/2020 (44-52)
Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA
Ludger Klimek1, Oliver Pfaar2, Margitta Worm3, Karl-Christian Bergmann3, Thomas Bieber4, Roland Buhl5, Jeroen Buters6, Ulf Darsow7, Thomas Keil8, Jörg Kleine-Tebbe9, Susanne Lau10, Marcus Maurer69, Hans Merk11, Ralph Mösges12,13,14, Joachim Saloga15, Petra Staubach15, Petra Stute16, Klaus Rabe17, Uta Rabe18, Claus Vogelmeier19, Tilo Biedermann7,20, Kirsten Jung21, Wolfgang Schlenter22, Johannes Ring23,24, Adam Chaker25,26, Wolfgang Wehrmann27, Sven Becker28, Norbert Mülleneisen29, Katja Nemat30,31, Wofgang Czech32, Holger Wrede33, Randolf Brehler34, Thomas Fuchs35, Peter-Valentin Tomazic36, Werner Aberer37, Antje Fink-Wagner38, Friedrich Horak39, Stefan Wöhrl40, Verena Niederberger-Leppin41, Isabella Pali-Schöll42,43, Wolfgang Pohl44, Regina Roller-Wirnsberger45, Otto Spranger38, Rudolf Valenta46, Mübecell Akdis47, Cezmi Akdis47, Karin Hoffmann-Sommergruber43, Marek Jutel48, Paolo Matricardi49, FranÇois Spertini50, Nikolai Khaltaev51, Jean-Pierre Michel52, Laurent Nicod53,54, Peter Schmid-Grendelmeier55, Eckard Hamelmann56, Thilo Jakob57, Thomas Werfel58, Martin Wagenmann59, Christian Taube60, Michael Gerstlauer67, Christian Vogelberg68, Jean Bousquet61,62,63,64,65,66, and Torsten Zuberbier3
1Zentrum für Rhinologie und Allergologie, Wiesbaden, 2Sektion Rhinologie und Allergologie, Klinik für Hals-, Nasen-und Ohrenheilkunde, Universitätsklinikum Gießen und Marburg, Philipps-Universität Marburg, 3Comprehensive Allergy Centre Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin, 4Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Bonn, 5III. Medizinische Klinik und Poliklinik Hämatologie, Internistische Onkologie und Pneumologie, Universitätsmedizin Mainz, 6Zentrum Allergie und Umwelt (ZAUM) Technische Universität und Helmholtz Zentrum München, 7Klinik und Poliklinik für Dermatologie und Allergologie der Technischen Universität München, 8Institut für klinische Epidemiologie und Biometrie, Julius-Maximilian-Universität, Würzburg, 9Allergie- und Asthma-Zentrum Westend, Berlin, 10Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin, Charité – Universitätsmedizin Berlin, 11Abteilung Dermatologie & Allergologie, RWTH Aachen Universität, 12Medizinische Fakultät der Universität zu Köln, 13CRI – Clinical Research International Ltd., Hamburg, 14ClinCompetence Cologne GmbH, Köln, 15Hautklinik, Universitätsmedizin, Johannes Gutenberg-Universität, Mainz, 16Europäische Vereinigung für Vitalität und Aktives Altern, Leipzig, 17Abteilung für Pneumologie, LungenClinic Grosshansdorf, 18Klinik für Allergologie, Johanniter-Krankenhaus im Fläming Treuenbrietzen GmbH, Treuenbrietzen, 19Klinik für Innere Medizin Schwerpunkt Pneumologie, Philipps-Universität Marburg, 20Einheit für Klinische Allergologie (EKA), Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, 21Praxis für Dermatologie, Immunologie und Allergologie, Erfurt, 22Ärzteverband Deutscher Allergologen, Dreieich, 23Haut- und Laserzentrum an der Oper, München, 24Academia: München, 25HNO-Klinik des Klinikums rechts der Isar, Technische Universität München, 26Zentrum Allergie und Umwelt München (ZAUM); Helmholtz Zentrum München, 27Praxis für Dermatologie und Allergologie, Münster, 28Klinik für Hals-, Nasen- und Ohrenheilkunde, Universität Tübingen, 29Asthma und Allergiezentrum Leverkusen, 30Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Dresden, 31Praxis für Kinderpenumologie/Allergologie am Kinderzentrum Dresden (Kid), Dresden, 32Klinik für Dermatologie, Universität Freiburg, 33Hals-, Nasenund Ohrenarzt, Nordrhein-Westfalen, 34Klinik für Allergologie, Berufsdermatologie und Umweltmedizin, Universitätsklinikum Münster, 35Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum, Georg-August-Universität, Göttingen, 36Klinische Abteilung für Allgemeine HNO, Medizinische Universität Graz, Österreich, 37Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Graz, Österreich, 38Global Allergy and Airways Patient Platform GAAPP, Wien, Österreich, 39Praxis für Hals-, Nasen- und Ohrenkrankheiten, Wien, Österreich, 40Floridsdorfer Allergiezentrum, Wien, Österreich, 41Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Medizinische Universität Wien, Österreich, 42Institut für Komparative Medizin, Interdisziplinäres Messerli Forschungsinstitut, Veterinärmedizinische Universität Wien und Medizinische Universität Wien, Österreich, 43Institut für Pathophysiologie und Allergieforschung, Medizinische Universität Wien, Österreich, 44Abteilung für Atmungs- und Lungenkrankheiten, Krankenhaus Hietzing, Wien, Österreich, 45Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Österreich, 46Institut für Pathophysiologie, Medizinische Universität Wien, Österreich, 47Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Schweiz, 48Department of Clinical Immunology, Medizinische Universität Breslau, Polen, 49Charité – Universitätsmedizin Berlin, 50Division of Allergy and Immunology, Centre Hospitalier Universitaire Vaudois, Lausanne, Schweiz, 51GARD Chairman, Genf, Schweiz, 52Department of Rehabilitation and Geriatrics, University of Geneva, Genf, Schweiz, 53Clinique Cecil, Hirslanden Gruppe, Lausanne, Schweiz, 54Abteilung Pneumologie, Centre hospitalier universitaire vaudois, Lausanne, Schweiz, 55Allergiestation, Dermatologische Klinik, Universitätsspital Zürich, Schweiz, 56Kinderzentrum Bethel, Evangelisches Klinikum Bethel, Universitätsmedizin OWL der Universität Bielefeld, 57Klinik für Dermatologie, Allergologie, Universitätsklinikum Gießen, UKGM, Justus-Liebig-Universität Gießen, 58Klinik fürDermatologie, Allergologie und Venerologie Medizinische Hochschule Hannover, 59HNO-Klinik, Universitätsklinikum Düsseldorf, 60Klinik für Pneumologie, Ruhrlandklinik, Universitätsmedizin Essen, 61MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, Frankreich, 62INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, 63Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, Frankreich, 64Euforea, Brussels, Belgien, 65Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, 66Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, 67Abteilung für Kinderpneumologie und Allergologie, Medizinische Universität Augsburg, 68Klinik für Kinderpneumologie und Allergologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, 69Dermatologische Allergologie, Allergie-Centrum-Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin
Correspondence to:
Prof. Dr. Ludger Klimek, Zentrum für Rhinologie und Allergologie, An den Quellen 10, 65183 Wiesbaden
Email: [email protected]
Position Paper
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic
Ludger Klimek, Oliver Pfaar, Margitta Worm, Thomas Eiwegger, Jan Hagemann, Markus Ollert, Eva Untersmayr, Karin Hoffmann-Sommergruber, Alessandra Vultaggio, Ioana Agache, Sevim Bavbek, Apostolos Bossios, Ingrid Casper, Susan Chan, Alexia Chatzipetrou, Christian Vogelberg, Davide Firinu, Paula Kauppi, Antonios Kolios, Akash Kothari, Andrea Matucci, Oscar Palomares, Zsolt Szépfalusi, Wolfgang Pohl, Wolfram Hötzenecker, Alexander R. Rosenkranz, Karl-Christian Bergmann, Thomas Bieber, Roland Buhl, Jeroen Buters, Ulf Darsow, Thomas Keil, Jörg Kleine-Tebbe, Susanne Lau, Marcus Maurer, Hans Merk, Ralph Mösges, Joachim Saloga, Petra Staubach, Uta Jappe, Klaus F. Rabe, Uta Rabe, Claus Vogelmeier, Tilo Biedermann, Kirsten Jung, Wolfgang Schlenter, Johannes Ring, Adam Chaker, Wolfgang Wehrmann, Sven Becker, Laura Freudelsperger, Norbert Mülleneisen, Katja Nemat, Wolfgang Czech, Holger Wrede, Randolf Brehler, Thomas Fuchs, Peter-Valentin Tomazic, Werner Aberer, Antje-Henriette Fink-Wagner, Fritz Horak, Stefan Wöhrl, Verena Niederberger-Leppin, Isabella Pali-Schöll, Wolfgang Pohl, Regina Roller-Wirnsberger, Otto Spranger, Rudolf Valenta, Mübecell Akdis, Paolo M. Matricardi, François Spertini, Nicolai Khaltaev, Jean-Pierre Michel, Larent Nicod, Peter Schmid-Grendelmeier, Marco Idzko, Eckard Hamelmann, Thilo Jakob, Thomas Werfel, Martin Wagenmann, Christian Taube, Erika Jensen-Jarolim, Stephanie Korn, Francois Hentges, Jürgen Schwarze, Liam O´Mahony, Edward F. Knol, Stefano del Giacco, Tomás Chivato Pérez, Jean Bousquet, Anna Bedbrook, Torsten Zuberbier, Cezmi Akdis, and Marek Jutel
Page No. 53
Abstract
Allergologie select, Volume 4/2020 (53-68)
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic
Ludger Klimek1, Oliver Pfaar2, Margitta Worm3, Thomas Eiwegger4,5,6, Jan Hagemann7, Markus Ollert8,9, Eva Untersmayr10, Karin Hoffmann-Sommergruber10, Alessandra Vultaggio11, Ioana Agache12, Sevim Bavbek13, Apostolos Bossios14,15, Ingrid Casper1,16,17, Susan Chan18, Alexia Chatzipetrou19, Christian Vogelberg20, Davide Firinu21, Paula Kauppi22, Antonios Kolios16,23, Akash Kothari4, Andrea Matucci11, Oscar Palomares24, Zsolt Szépfalusi25, Wolfgang Pohl26, Wolfram Hötzenecker27, Alexander R. Rosenkranz28, Karl-Christian Bergmann3, Thomas Bieber29, Roland Buhl30, Jeroen Buters31, Ulf Darsow32, Thomas Keil33, Jörg Kleine-Tebbe34, Susanne Lau35, Marcus Maurer98, Hans Merk36, Ralph Mösges37,38,39, Joachim Saloga40, Petra Staubach40, Uta Jappe41, Klaus F. Rabe42, Uta Rabe42, Claus Vogelmeier44, Tilo Biedermann32,45, Kirsten Jung46, Wolfgang Schlenter47, Johannes Ring48,49, Adam Chaker50,51, Wolfgang Wehrmann52, Sven Becker53, Laura Freudelsperger7, Norbert Mülleneisen54, Katja Nemat55, Wolfgang Czech56, Holger Wrede57, Randolf Brehler58, Thomas Fuchs59, Peter-Valentin Tomazic60, Werner Aberer61, Antje-Henriette Fink-Wagner62, Fritz Horak63, Stefan Wöhrl64, Verena Niederberger-Leppin65, Isabella Pali-Schöll10,66,67, Wolfgang Pohl68, Regina Roller-Wirnsberger69, Otto Spranger70, Rudolf Valenta71,94,95,96, Mübecell Akdis72, Paolo M. Matricardi73, François Spertini74, Nicolai Khaltaev75, Jean-Pierre Michel76, Larent Nicod77, Peter Schmid-Grendelmeier78, Marco Idzko79, Eckard Hamelmann80, Thilo Jakob81, Thomas Werfel82, Martin Wagenmann83, Christian Taube84, Erika Jensen-Jarolim10,66, Stephanie Korn30, Francois Hentges85, Jürgen Schwarze86, Liam O´Mahony87, Edward F. Knol88, Stefano del Giacco89, Tomás Chivato Pérez90, Jean Bousquet91,92,93,94,95, Anna Bedbrook91, Torsten Zuberbier3, Cezmi Akdis72, and Marek Jutel96,97
1Zentrum für Rhinologie und Allergologie, Wiesbaden, 2HNO-Universitätsklinik Marburg, Sektion Rhinologie und Allergologie, Medizinische Fakultät Marburg, Philipps-Universität Marburg, 3Comprehensive Allergy Centre Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin, Germany, 4Translational Medicine Program, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children, Toronto, Ontario, Canada, 5Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, Ontario, Canada, 6Department of Immunology, University of Toronto, Toronto, Ontario, Canada, 7Hals-, Nasen-, Ohrenklinik und Poliklinik, Universitätsmedizin Mainz, Germany 8Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxemburg, 9Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, University of Southern Denmark, Odense, Denmark, 10Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medizinische Fakultät der Universität Wien, Vienna, Austria, 11Immunoallergology Unit, Careggi University Hospital, Florence, Italy, 12Transylvania University, Brasov, Romania, 13Ankara University, School of Medicine, Department of Chest Disease, Division of, Immunology and Allergy, Ankara, Turkey, 14Abteilung für Atemwegsmedizin und Allergie, Karolinska University Hospital, Huddinge und Abteilung für Medizin, Huddinge, Karolinska Institutet, Stockholm, Sweden, 15Zentrum für Allergieforschung, Karolinska Institutet, Stockholm, Sweden, 16Department of Immunology, University Hospital Zürich, Zürich, Switzerland, 17Faculty of Medicine, University of Zürich, Zürich, Switzerland, 18Guy’s and St. Thomas’ NHS Foundation Trust, Westminster Bridge Road, London, United Kingdom, King’s College London School of Life Course Sciences & School of Immunology & Microbial Sciences, King’s Health Partners, United Kingdom, 19Allergy Unit 2nd Department of Dermatology and Venereology, National University of Athens, Medical School, University General Hospital „ATTIKON“, Athen, Greece, 20Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Kinder- und Jugendmedizin, Fachbereich Kinderpneumologie/Allergologie, Dresden, Germany 21Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, 22Abteilung für Allergie, Entzündungszentrum, Universitätsklinikum Helsinki, Helsinki, Finland, 23Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA, 24Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Spain, 25Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie, Universitätsklinik für Kinder- und Jugendheilkunde, Comprehensive Center for Pediatrics, Medizinische Universität Wien, Vienna, Austria, 26Abteilung für Atmungs- und Lungenerkrankungen, Krankenhaus Hietzing, Vienna, Austria, 27Abteilung für Dermatologie und Venerologie, Kepler Universitätsklinikum, Linz, Austria, 28Klinische Abteilung für Nephrologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Austria, 29Klinik für Dermatologie und Allergologie, Universität Bonn, Bonn, 30Schwerpunkt Pneumologie, III. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz, Mainz, 31Zentrum Allergie und Umwelt (ZAUM) Technische Universität und Helmholtz Zentrum München, 32Klinik und Poliklinik für Dermatologie und Allergologie der Technischen Universität München, 33Institut für Klinische Epidemiologie und Biometrie, Universität Würzburg, 34Allergie- und Asthma-Zentrum Westend, Berlin, 35Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin, Charité – Universitätsmedizin Berlin, 36Abteilung Dermatologie und Allergologie, RWTH Universität, Aachen, 37Medizinische Fakultät der Universität zu Köln, Cologne 38CRI – Clinical Research International Ltd., Hamburg, 39ClinCompetence Cologne GmbH, Köln, Cologne 40Hautklinik und Poliklinik, Universitätsmedizin Mainz, 41Forschungsgruppe Klinische und Molekulare Allergologie des Forschungszentrums Borstel, Airway Research Center North (ARCN), Mitglied des Deutschen Zentrums für Lungenforschung (DZL); Interdisziplinäre Allergie-Ambulanz, Medizinische Klinik III, Universität zu Lübeck, 42LungenClinic Grosshansdorf, Großhansdorf, 43Klinik für Allergologie, Johanniter-Krankenhaus im Fläming Treuenbrietzen GmbH, Treuenbrietzen, 44Klinik für Innere Medizin Schwerpunkt Pneumologie, Philipps-Universität Marburg, 45Einheit für Klinische Allergologie (EKA), Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, 46Praxis für Dermatologie, Immunologie und Allergologie, Erfurt, 47Ärzteverband Deutscher Allergologen, Dreieich, 48Haut- und Laserzentrum an der Oper, München, Munich, 49Academia München, 50HNO-Klinik, Universitätsklinik TUM, München, 51ZAUM, Helmholtz Zentrum München, Munich 52Praxis für Dermatologie und Allergologie, Münster, 53Klinik für Hals-, Nasen- und Ohrenheilkunde, Universität Tübingen, 54Asthma und Allergiezentrum Leverkusen, 55Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Dresden; Praxis für Kinderpenumologie/Allergologie am Kinderzentrum Dresden (Kid), Dresden, 56Praxis und Klinik für Dermatologie/Allergologie am Schwarzwald-Baar Klinikum, Villingen-Schwenningen, 57Hals-, Nasen- und Ohrenarzt, Nordrhein-Westfalen, 58Universitätsklinikum Münster, Klinik für Hautkrankheiten, Ambulanz für Allergologie, Berufsdermatologie und Umweltmedizin, Münster, 59Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum, Georg-August-Universität, Göttingen, Germany 60Klinische Abteilung für allgemeine HNO, Medizinische Universität Graz, Austria, 61Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Graz, Austria, 62Global Allergy and Airways Patient Platform GAAPP, Vienna, Austria, 63Allergiezentrum Wien West, Vienna, Austria, 64Floridsdorfer Allergiezentrum, Vienna, Austria, 65Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Medizinische Universität Vienna, Austria, 66Komperative Medizin, Interdisziplinäres Messerli Forschungsinstitut, Veterinärmedizinische Universität Wien, Medizinische Universität Wien, 67Institut für Pathophysiologie und Allergieforschung, Medizinische Universität Wien, 68Abteilung für Atmungs- und Lungenerkrankungen, Krankenhaus Hietzing, Vienna, Austria, 69Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Austria, 70Österreichische Lungenunion, Vienna, Austria, 71Immunopathologie, Abteilung für Pathophysiologie und Allergieforschung, Zentrum für Pathophysiologie, Infektiologie und Immunologie, Medizinische Universität Wien, Austria, 72Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, 73Charité – Universitätsmedizin Berlin, 74Division of Allergy and Immunology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 75GARD Chairman, Genf, Switzerland, 76Department of Rehabilitation and Geriatrics, University of Geneva, Genf, Switzerland, 77Clinic Cecil of Hirslanden Group of Lausanne; Centre Hôpitalier Universitaire du canton de Vaud Lausanne, Switzerland, 78Allergiestation, Dermatologische Klinik, Universitätsspital Zürich, Switzerland, 79Klinische Abteilung für Pneumologie, Universitätsklinik für Innere Medizin II, Medizinische Universität Wien, Austria, 80Kinderzentrum Bethel, Evangelisches Klinikum Bethel, Universitätsmedizin OWL der Universität Bielefeld, 81Klinik für Dermatologie und Allergologie, Universitätsklinikum Gießen, UKGM, Justus-Liebig-Universität, Gießen, 82Klinik für Dermatologie, Allergologie und Venerologie Medizinische Hochschule Hannover, 83HNO-Klinik, Universitätsklinikum Düsseldorf, 84Universitätsklinikum Essen (AöR), Germany 85Service Immunologie-Allergologie Centre Hospitalier de Luxembourg, Luxemburg, 86Kinderleben und Gesundheit, Universität von Edinburgh, United Kingdom, 87Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Irland, 88Departments of Immunology, Dermatology and Allergology, University Medical Center Utrecht, the Netherlands, 89Università degli Studi di Cagliari, Cagliari, Italy, 90University Foundation San Pablo CEU, Madrid, Spain, 91MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, 92INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, France, 93Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, 94Euforea, Brussels, Belgium, 95Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Germany 96Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland, 97ALL-MED Medical Research Institute, Wrocław, Poland, and 98Dermatologische Allergologie, Allergie-Centrum-Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin, Germany
Background: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for “social distancing” and the fear of patients becoming infected during a visit to a medical facility have led to a drastic decrease in personal doctor-patient contacts. This affects both acute care and treatment of the chronically ill. The immune response after SARS-CoV-2 infection is so far only insufficiently understood and could be altered in a favorable or unfavorable way by therapy with monoclonal antibodies. There is currently no evidence for an increased risk of a severe COVID-19 course in allergic patients. Many patients are under ongoing therapy with biologicals that inhibit type 2 immune responses via various mechanisms. There is uncertainty about possible immunological interactions and potential risks of these biologicals in the case of an infection with SARS-CoV-2. Materials and methods: A selective literature search was carried out in PubMed, Livivo, and the internet to cover the past 10 years (May 2010 – April 2020). Additionally, the current German-language publications were analyzed. Based on these data, the present position paper provides recommendations for the biological treatment of patients with allergic and atopy-associated diseases during the COVID-19 pandemic. Results: In order to maintain in-office consultation services, a safe treatment environment must be created that is adapted to the pandemic situation. To date, there is a lack of reliable study data on the care for patients with complex respiratory, atopic, and allergic diseases in times of an imminent infection risk from SARS-CoV-2. Type-2-dominant immune reactions, as they are frequently seen in allergic patients, could influence various phases of COVID-19, e.g., by slowing down the immune reactions. Theoretically, this could have an unfavorable effect in the early phase of a SARS-Cov-2 infection, but also a positive effect during a cytokine storm in the later phase of severe courses. However, since there is currently no evidence for this, all data from patients treated with a biological directed against type 2 immune reactions who develop COVID-19 should be collected in registries, and their disease courses documented in order to be able to provide experience-based instructions in the future. Conclusion: The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and spontaneous urticaria should be continued as usual in patients without suspected infection or proven SARS-CoV-2 infection. If available, it is recommended to prefer a formulation for self-application and to offer telemedical monitoring. Treatment should aim at the best possible control of difficult-to-control allergic and atopic diseases using adequate rescue and add-on therapy and should avoid the need for systemic glucocorticosteroids. If SARS-CoV-2 infection is proven or reasonably suspected, the therapy should be determined by weighing the benefits and risks individually for the patient in question, and the patient should be involved in the decision-making. It should be kept in mind that the potential effects of biologicals on the immune response in COVID-19 are currently not known. Telemedical offers are particularly desirable for the acute consultation needs of suitable patients.Correspondence to:
Prof. Dr. Ludger Klimek, Zentrum für Rhinologie und Allergologie, An den Quellen 10, 65183 Wiesbaden
Email: [email protected]
Original
Climate change in Switzerland: Impact on hazel, birch, and grass pollen on the basis of half a century of pollen records (1969 – 2018)
Thomas Frei
Page No. 69
Abstract
Allergologie select, Vol. 4/2020 (69-75)
Climate change in Switzerland: Impact on hazel, birch, and grass pollen on the basis of half a century of pollen records (1969 – 2018)
Thomas Frei
Research and Consulting, Arni, Switzerland
As indicated by the Intergovernmental Panel on Climate Change (IPCC), human activities are estimated to have caused ~ 1.0 °C of global warming above pre-industrial levels. The impact of this global warming is diverse and pertains also plant biology. The start of the pollen season as well as the observed quantities of pollen have been considered indicators of the impact of climate change. Switzerland has one of the longest pollen time series now – more than half a century. It has been tested whether the impact of climate change is robust by checking with this long time series of different pollen like hazel, birch, and grass as prominent representatives of triggers of hay fever. The results indicate that based on a time series of 50 years, the pollen seasons of hazel, birch, and grass started earlier as the temperature increased. Comparing the annual amount of pollen, a relevant increase is only observed for hazel. However, it must be considered that in the observed 50 years there was a land use change from grass land to built-up land due to the increase of population, and yet certain pollen counts increased considerably.Correspondence to:
Dr. sc. nat. Thomas Frei, Research and Consulting, 8905 Arni, Switzerland
Email: [email protected]
Original
Obesity-associated asthma in childhood
Maria Mangova1,2, Tobias Lipek1,2, Maike vom Hove1,2, Antje Körner1, Wieland Kiess1,2, Regina Treudler2,3, and Freerk Prenzel1,2
Page No. 76
Abstract
Allergologie select, Volume 4/2020 (76-84)
Obesity-associated asthma in childhood
Maria Mangova, Tobias Lipek, Maike vom Hove, Antje Körner, Wieland Kiess, Regina Treudler, and Freerk Prenzel
1University of Leipzig Medical Center, Department for Pediatrics, 2LICA – Leipzig Interdisciplinary Center for Allergy (Comprehensive Allergy Center), and 3University of Leipzig Medical Center, Department of Dermatology, Venereology and Allergy, Leipzig, Germany
Obesity and bronchial asthma are very common diseases in children and adolescents, associated with a considerable burden of disease, reduced quality of life and comorbidities. Obesity is a significant risk factor for bronchial asthma. On the one hand, obesity leads to changes in the mechanics and function of the lungs and chest. On the other hand, obesity-associated inflammatory processes with increased production of leptin and cytokines may trigger bronchial inflammation with the appearance of asthmatic symptoms. The diseases are also linked by genetic factors. Physical activity and weight reduction have a significant benefit. Pharmacotherapy must be based on the pattern of inflammation. This article summarizes the current state of the literature on the association of asthma and obesity and presents current and possible future treatment options.Correspondence to:
Dr. med. Freerk Prenzel, University of Leipzig Medical Center, Department for Pediatrics, Liebigstr. 20a, 04103, Leipzig, Germany
Email: [email protected]
Review
Atopic dermatitis and psychosocial comorbidities – What’s new?
Paula Kage, Julia Zarnowski, Jan-Christoph Simon, and Regina Treudler
Page No. 86
Abstract
Allergologie select, Volume 4/2020 (86-96)
Atopic dermatitis and psychosocial comorbidities – What’s new?
Paula Kage, Julia Zarnowski, Jan-Christoph Simon, and Regina Treudler
Department of Dermatology, Venereology and Allergology, Leipzig Interdisciplinary Center for Allergology – LICA-CAC, University of Leipzig, Germany
Atopic dermatitis (AD) is a chronic inflammatory disease. During the last years, researchers have focused on a variety of associated comorbidities, especially psychosocial disease. This article aims at giving an overview over recent data. A systematic literature research was performed in PubMed including data from the time period January 1, 2018 until March 1, 2020. Patients with AD frequently suffer from cocomitant depression, anxiety, and attention deficit hyperactivity disorder. There is less evidence about the relation between AD and schizophrenia, eating disorder, and obsessive compulsive disorder. There is still great need for research in the connection between AD and psychosocial disease, particularly about the pathogenesis and the influence of new therapies.Correspondence to:
Dr. med. Paula Kage, Department of Dermatology, Venereology and Allergology, Leipzig Interdisciplinary Center for Allergology – LICA-CAC, University of Leipzig, Philipp-Rosenthal-Straße 23, 04103 Leipzig, Germany
Email: [email protected]
Review
Insect hypersensitivity beyond bee and wasp venom allergy
Wolfgang Hemmer and Felix Wantke
Page No. 97
Abstract
Allergologie select, Volume 4/2020 (97-104)
Insect hypersensitivity beyond bee and wasp venom allergy
Wolfgang Hemmer and Felix Wantke
Floridsdorf Allergy Center, Vienna
The bites of blood-feeding insects regularly induce sensitization to salivary proteins and cause local hypersensitivity reactions in over 90% of the population, representing either an IgE-mediated immediate wheal and flare reaction or a T celldriven delayed papule. Long-lasting large local reactions and bullous reactions may cause significant discomfort and reduction in quality-of-life. Anaphylaxis is rarely reported though proven for several insects, above all mosquitoes, horse flies, and kissing bugs. Recently, salivary gland proteins have been thoroughly studied in some blood-feeding insect species, and several allergens have been identified. Interestingly, many of them belong to the same protein families as the wellknown honeybee and wasp venom allergens (phospholipases, hyaluronidases, antigens 5, serine proteases) though sequence identities are mostly low. There is still insufficient evidence for the proposed cross-reactivity between salivary proteins from blood-feeding insects and Hymenoptera venom allergens.Correspondence to:
Wolfgang Hemmer, PhD, Floridsdorf Allergy Center, Pius-Parsch-Platz 1/3, 1210 Vienna, Austria
Email: [email protected]
Case Report
Unusual allergen in a butcher with respiratory symptoms
Ingrid Sander, Claus Keller, Christina Czibor, Ursula Meurer, Rolf Merget and Monika Raulf
Page No. 105
Abstract
Allergologie select, Volume 4/2020 (105-109) ©2020 Dustri-Verlag Dr. K. Feistle ISSN 2512-8957 DOI 10.5414/ALX02126E e-pub: December 2, 2020 Received August
Unusual allergen in a butcher with respiratory symptoms
Ingrid Sander1, Claus Keller2, Christina Czibor1, Ursula Meurer1, Rolf Merget1 and Monika Raulf1
1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, and 2Medical Practice for Pulmonary and Bronchial Medicine, Allergology and Environmental Medicine, Frankfurt am Main, Germany
A 37-year-old butcher developed respiratory symptoms during sausage and chicken production in a large company. In addition to various spices, the enzyme transglutaminase was a possible cause. The lung function test showed mild partial reversible airway obstruction and severe bronchial hyperresponsiveness. The IgE test showed sensitizations to various spice mixtures, coriander (0.74 kU/L), and to the ImmunoCAPbound transglutaminase preparation from the workplace (7.12 kU/L). The skin prick tests with this transglutaminase were also positive. In the immunoblot of this preparation, a 40-kD protein reacted with the patient’s IgE and was identified as transglutaminase from Streptomyces mobaraensis by inhibition experiments. This is the first case of a butcher with an allergy to transglutaminase. After moving to a small enterprise without enzyme use, his symptoms improved. Sensitization and the course of the symptoms indicate a dominant role of transglutaminase in the patient’s allergic asthma.Correspondence to:
Dr. Ingrid Sander, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum, Center of Allergology/Immunology, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
Email: [email protected]
Case Report
Microbial contamination in water-based metalworking fluid as trigger for occupational hypersensitivity pneumonitis – development of specific IgG tools for a suspected clinical case
Sabine Kespohl, Isabell Warfolomeow, Gerd Schneider, Silke Maryska, Ursula Meurer, and Monika Raulf
Page No. 110
Abstract
Allergologie select, Volume 4/2020 (110-117)
Microbial contamination in water-based metalworking fluid as trigger for occupational hypersensitivity pneumonitis – development of specific IgG tools for a suspected clinical case
Sabine Kespohl1, Isabell Warfolomeow2, Gerd Schneider3, Silke Maryska1, Ursula Meurer1, and Monika Raulf1
1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, 2German Social Accident Insurance Institution for the Woodworking and Metalworking Industries, BGHM, Mainz, and 3Institute for Occupational Safety and Health of the German Social Accident Insurance (IFA), St. Augustin, Germany
Microbially contaminated metal-working fluid (MWF) can cause respiratory symptoms in exposed workers in the form of exogenous allergic alveolitis/hypersensitivity pneumonitis (HP). The diagnosis of HP is based, among others, on the identification of the culprit and the detection of corresponding specific IgG antibodies (sIgG) in the patient’s serum. Commercial antigen tools for the detection of these HP triggers are rarely available; therefore, antigens from contaminated MWF workplace samples were isolated exemplarily for diagnosis of a suspected HP case. Various MWF-specific bacteria were identified in the workplace samples, including Pseudomonas oleovorans, Pseudomonas alcaliphila, Pseudomonas spec., Paenibacillus glucanolyticus, and Corynebacterium amycolatum. The sIgG antigen binding, detected by ImmunoCAP system against MWF antigens from workplace samples and against the identified bacterial antigens, was much stronger in the patient serum compared to selected reference sera. The highest sIgG concentrations in the patient’s serum could be determined against Pseudomonas antigens. Inhibition tests showed cross-reactions of MWF and Pseudomonas antigens, whereby the Pseudomonas antigens cross-reacted less with each other. For in-vitro diagnosis in case of suspected HP caused by contaminated MWF, workplacerelated antigens are now available.Correspondence to:
Dr. Sabine Kespohl, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum
Email: [email protected]
Case Report
Severe bronchial reaction to provocation with fish and crustaceans
Alexandra M. Preisser, Alexander M. Kraft, and Volker Harth
Page No. 118
Abstract
Allergologie select, Volume 4/2020 (118-123)
Severe bronchial reaction to provocation with fish and crustaceans
Alexandra M. Preisser, Alexander M. Kraft, and Volker Harth
Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
The specific inhalation challenge (SIC), a workplace-related inhalation exposure test, is used to identify allergic asthma when symptoms such as coughing, wheezing, or dyspnea occur at the workplace. Its use is risky. A cook (28 years old) has been complaining of rhinoconjunctivitis and contact urticaria while preparing seafood for 3 years. He continues to work, now wears gloves, no longer tastes fish dishes, and receives anti-obstructive therapy (ICS, LABA). Methacholine (MCH) testing for bronchial hyperreactivity (BHR) shows mild BHR (PD100;sRaw: 0.28 mg MCH), skin and blood tests show type I sensitization to fish and crustacean proteins. In SIC with fried shrimps, rhinoconjunctivitis, coughing and distance wheezing, FEV1 drop > 20%, sRaw increase to 9.6 kPa*s and angioedema occur. Since routine tests showed only a moderate BHR, the suspicion of an occupational disease was formulated very late in the medical examination process. Only the SIC showed the severity of the cook’s bronchial asthma.Correspondence to:
PD Dr. med. Alexandra M. Preisser, Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf, Seewartenstraße 10, 20459 Hamburg, Germany
Email: [email protected]
Case Report
Occupational diisocyanate asthma of a female professional driver – the importance of allergological diagnostics
Christian Eisenhawer, Monika Raulf, and Rolf Merget
Page No. 124
Abstract
Allergologie select, Vol. 4/2020 (124-128)
Occupational diisocyanate asthma of a female professional driver – the importance of allergological diagnostics
Christian Eisenhawer, Monika Raulf, and Rolf Merget
Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Bochum, Germany
Diisocyanates continue to be one of the most frequent causes of occupational asthma worldwide. They are still indispensable in industrial use as components of coatings, glues, and polyurethane foams. In Germany, respiratory diseases due to diisocyanates can be compensated by the statutory accident insurance (according to BK-Nr. 1315). The present case report shows a rare case of sensitization against diisocyanates verified by skin prick test and serological testing. Due to these findings, a modified inhalation test with an extremely low initial diisocyanate concentration in the laboratory was performed, and a positive reaction could be detected already after an extremely low diisocyanate concentration. In addition, increases of fractional exhaled nitric oxide (FeNO) and eosinophils in induced sputum after inhalation testing were seen. The present case constellation underlines the particular importance of allergological tests for diagnostic clarification of the diagnosis of diisocyanate asthma.Correspondence to:
Dr. med. Christian Eisenhawer, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Competence Center Medicine, Bürkle-de-la Camp-Platz 1, 44789 Bochum, Germany
Email: [email protected]
Case Report
Occupational allergic contact urticaria to tropomyosin from squid
Daniel Wilfinger, Annette Kuehn, Szandra Takacs, Evgenia Galli-Novak, Barbara Machan und Werner Aberer
Page No. 129
Abstract
Allergologie select, Vol. 4/2020 (129-134)
Occupational allergic contact urticaria to tropomyosin from squid
Daniel Wilfinger1, Annette Kuehn2, Szandra Takacs1, Evgenia Galli-Novak1, Barbara Machan1 und Werner Aberer3
1Department of Occupational Diseases and Occupational Medicine, AUVA Rehabilitation Clinic Tobelbad, Tobelbad, Austria, 2Department of Infection and Immunity, Luxembourg Institute of Health, Luxemburg, and 3Department of Dermatology and Venerology, Medical University Graz, Graz, Austria
A cook’s mate working in an Austrian restaurant reported acutely occurring urticarial skin lesions after processing and cooking squid. The prick-to-prick test with squid showed a ++ positive urticarial reaction. Elevated specific IgE antibody levels to squid, shrimp, and house dust mites as well as to tropomyosin from shrimp and house dust mite could be detected in the ImmunoCAP. By means of immunoblot and ELISA, a reaction to squid extract as well as increased IgE antibody levels to squid and tropomyosin from squid could be detected. The patient was diagnosed with a clinically and occupationally relevant type I allergy to squid with cross-reaction to tropomyosin of other invertebrates and therefore recognized as an occupational disease.Correspondence to:
Dr. med. univ. Daniel Wilfinger, Department of Occupational Diseases and Occupational Medicine, AUVA Rehabilitation Clinic Tobelbad, Tobelbad, Austria, Dr.-Georg-Neubauer-Straße 6, 8144 Tobelbad, Austria
Email: [email protected]
Original
Can nasal acetylsalicylic acid challenge predict the severity of non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (N-ERD)?
Ulrike Förster-Ruhrmann, Anne-Kristin Tietz, Jonghui Kim, Uta Liebers, Agnieszka J. Szczepek and Heidi Olze
Page No. 135
Abstract
Allergologie select, Vol. 4/2020 (135-143)
Can nasal acetylsalicylic acid challenge predict the severity of non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (N-ERD)?
Ulrike Förster-Ruhrmann1, Anne-Kristin Tietz1, Jonghui Kim1, Uta Liebers2, Agnieszka J. Szczepek3 and Heidi Olze1,3
1CVK Department of Otorhinolaryngology, Head and Neck Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, 2Department of Pulmonology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin
Institute of Health, Berlin, and 3CCM Department of Otorhinolaryngology, Head and Neck Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
Background: Non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (N-ERD) complicates the clinical course of chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma. We aimed to determine the detection rate of NERD in patients with CRSwNP, asthma, and history of NSAID intolerance using nasal challenge with acetylsalicylic acid (ASA) and the relationship between the severities of response to ASA challenges and the grade of N-ERD. Materials and methods: Three groups of patients were included: CRSwNP with asthma and clinical history of analgesics intolerance (CRSwNP-AAI n = 18), CRSwNP with asthma but without a clinical history of analgesics intolerance (CRSwNP-A n = 20), and CRSwNP without asthma or analgesics intolerance (n = 18). All subjects were challenged nasally with 16 mg ASA and monitored with active anterior rhinomanometry. Rhinological (nasal polyp score), pulmonary (spirometry, Asthma Control Test (ACT), and asthma treatment), and psychometric questionnaire scores were recorded and correlated with rhinomanometric data following nasal challenges (flow depressions and symptom scores). Results: Nasal ASA challenge detected N-ERD in 96.7% of CRSwNP-AAI patients and 45% of CRSwNP-A patients. No N-ERD was seen in the CRSwNP group. The control grade of asthma measured with ACT scores was significantly lower in the groups CRSwNP-AAI (MV 18.22) and CRSwNP-A (MV 19.75) when compared to the CRSwNP group (MV 24.39) (p = 0.000). In the CRSwNP-AAI group, 11 patients had uncontrolled asthma (61%), and in the CRSwNP-A group, 9 patients had uncontrolled asthma (45%). No correlation was found between rhinology and pulmonary parameters, nasal symptoms, and the severity of nasal ASA challenges. Specific reactions were detectable under the therapy of prednisolone and omalizumab. Conclusion: N-ERD might not always be detected by screening a patient’s medical history. Nasal ASA challenges are recommended in patients with CRSwNP and asthma. The nasal challenge with ASA positively confirms the N-ERD diagnosis. Moreover, N-ERD is a differential diagnosis in patients with severe asthma with the need for prednisolone or omalizumab therapy. The severity of the reaction to the ASA challenge in controlled and uncontrolled asthma patients is independent of the grade of N-ERD.Correspondence to:
Dr. Ulrike Förster-Ruhrmann, Department of Otorhinolaryngology, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Email: [email protected]
